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Abstract
Background: Pentavalent antimonials have been the first line treatment for dermal leishmaniasis in Colombia for over 30
years. Miltefosine is administered as second line treatment since 2005. The susceptibility of circulating populations of
Leishmania to these drugs is unknown despite clinical evidence supporting the emergence of resistance.
Methodology/Principal Findings: In vitro susceptibility was determined for intracellular amastigotes of 245 clinical strains of
the most prevalent Leishmania Viannia species in Colombia to miltefosine (HePC) and/or meglumine antimoniate (SbV); 163,
(80%) were evaluated for both drugs. Additionally, susceptibility to SbV was examined in two cohorts of 85 L. V. panamensis
strains isolated between 1980–1989 and 2000–2009 in the municipality of Tumaco. Susceptibility to each drug differed
among strains of the same species and between species. Whereas 68% of L. V. braziliensis strains presented in vitro
resistance to HePC, 69% were sensitive to SbV. Resistance to HePC and SbV occurred respectively, in 20% y 21% of L.
panamensis strains. Only 3% of L. V. guyanensis were resistant to HePC, and none to SbV. Drug susceptibility differed
between geographic regions and time periods. Subpopulations having disparate susceptibility to SbV were discerned
among L. V. panamensis strains isolated during 1980–1990 in Tumaco where resistant strains belonged to zymodeme 2.3,
and sensitive strains to zymodeme 2.2.
Conclusions/Significance: Large scale evaluation of clinical strains of Leishmania Viannia species demonstrated species,
population, geographic, and epidemiologic differences in susceptibility to meglumine antimoniate and miltefosine, and
provided baseline information for monitoring susceptibility to these drugs. Sensitive and resistant clinical strains within each
species, and zymodeme as a proxy marker of antimony susceptibility for L. V. panamensis, will be useful in deciphering
factors involved in susceptibility and the distribution of sensitive and resistant populations.
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Introduction
Pentavalent antimonial drugs, (sodium stibogluconate and
meglumine antimoniate) have been the first-line monotherapeutic
treatment for dermal leishmaniasis in Central and South America
for decades. Parenteral administration, volumes of drug requiring
divided doses in adults, frequent and potentially severe adverse
effects, and the logistical challenges of accessing medical supervi-
sion of therapy contribute to interruption and abandonment of
treatment, clinical failure, and loss of susceptibility [1,2,3].
Miltefosine (hexadecylphosphocholine), an oral drug originally
developed for treatment of cancer, was approved in 2005 for the
treatment of cutaneous leishmaniasis in adults and children in
Colombia, and is administered as second line treatment in patients
having contraindications or who fail to respond to antimonial
drugs. Miltefosine has demonstrated efficacy comparable to
pentavalent antimonials against infection caused by Leishmania
Viannia panamensis in Colombia [4,5], L. V. guyanensis [6] and L. V.
braziliensis in Brazil [7] and L. V. braziliensis in Bolivia [8].
Nevertheless, treatment failures and relapses have been observed
for both treatments in these and other randomized controlled
clinical trials [5,9].
Multiple factors contribute to the outcome of treatment,
including those of the host (immune status, pharmacokinetics,
pharmacogenetics, drug metabolism, adherence to treatment),
pharmacological properties of the drug (formulation and pharma-
codynamics) and parasite characteristics (biochemical and molec-
ular differences among species and strains) [4,10]. Evidence for the
PLOS Neglected Tropical Diseases | www.plosntds.org 1 May 2014 | Volume 8 | Issue 5 | e2871
emergence drug resistance to antimonial drugs [11,12] and
miltefosine [13,14] has been reported for visceral and cutaneous
leishmaniasis. Although the role of drug susceptibility in treatment
failure has been difficult to establish because therapeutic response
is multifactorial, prospective analyses of strains isolated prior to
treatment and at failure have demonstrated that loss of suscep-
tibility to antimony and to miltefosine can contribute to treatment
failure in dermal leishmaniasis [12,13].
Reports based on clinical response to different drugs in diverse
geographical settings indicate wide variation in effectiveness
[4,6,7,8,15]. In Colombia, where L. V. panamensis is the predom-
inant species isolated from civilian patient populations [16,17,18],
91% of patients responded to miltefosine treatment, whereas only
53% of patients responded in Guatemala, where L. mexicana and
L. V. braziliensis are common [4]. Cutaneous leishmaniasis caused
by L. V. braziliensis in Guatemala was highly responsive to sodium
stibogluconate [19] whereas disease caused by L. V. guyanensis was
poorly responsive to treatment with meglumine antimoniate in
Brazil [15] but highly responsive in Peru [20]. Although some of
these reports are not based on randomized, controlled clinical
trials, they portray the therapeutic response in endemic settings.
In vitro evidence of inter species differences in the susceptibility
of Leishmania to antileishmanial drugs has also been reported based
on small numbers of strains of diverse species isolated from
patients with visceral as well as cutaneous disease [21,22].
Technical constraints in evaluating EC50 based on intracellular
survival of clinical strains of Leishmania have limited routine or
large scale assessment of drug susceptibility, and prevented the
understanding of drug susceptibility in the context of prevention
and control.
This large scale study of susceptibility to drugs in use in
Colombia documented significant differences in susceptibility to
miltefosine and meglumine antimoniate among strains of the
same species and between species of the Viannia subgenus, as
well as geographic variation in drug susceptibility of populations
of these species. Additionally, this analysis demonstrated for the
first time, intrinsic differences in the susceptibility to meglumine
antimoniate between phenotypically distinct populations of
L. V. panamensis.
Materials and Methods
Study design
This study sought to determine the susceptibility of the most
prevalent species of Leishmania in Colombia to antileishmanial
drugs currently in use, and to explore possible geographic
variations in drug susceptibility of the corresponding parasite
populations. The in vitro susceptibility of clinical strains of L. V.
panamensis, L. V. braziliensis and L. V. guyanensis isolated at
diagnosis from patients who acquired infection in foci of
transmission in the Pacific, Andean, Orinoquı´a and Amazon
regions of Colombia was evaluated. Since treatment with
pentavalent antimonials has been the standard of care in
Colombia since 1980, we also examined whether the susceptibility
to SbV of L. V. panamensis, the most prevalent species among
civilian patients, changed over the 10 year periods from 1980–
1989 and 2000–2009 in two foci of transmission in the
municipality of Tumaco on the Pacific coast of Colombia. Clinical
and community based studies conducted in Tumaco since 1980
have contributed to the collection and characterization of clinical
strains based on isoenzyme polymorphism profiles (zymodeme)
[16]. These resources and demographic and epidemiologic
variables (residence within focus of transmission, age, sex and
occupation) of the corresponding patients in these endemic foci
were exploited to examine epidemiologic associations.
Strains
All Leishmania Viannia strains were isolated at diagnosis from
patients with cutaneous lesions by medical personnel in two
national reference centers for leishmaniasis, and cryopreserved in
liquid nitrogen in the biobanks of these centers: Centro Internacional
de Entrenamiento e Investigaciones Me´dicas, CIDEIM, Cali, and the
Centro Dermatolo´gico Federico Lleras Acosta, CDFLLA, Bogota´, Colom-
bia. In vitro susceptibility was evaluated within four passages from
isolation. Species identification was achieved by isoenzyme
electrophoresis or indirect immunofluorescence using species-
specific monoclonal antibodies as described elsewhere [16,17].
Prior to conducting drug susceptibility assays, the species identity
was re-confirmed for approximately 70% of the strains included in
this study.
The proportion of strains of each species that was evaluated was
based on the relative prevalence of the species in each of the
regions of high transmission; 245 strains were evaluated: 163 for
both drugs, plus 41 for SbV only and 41 for HePC only. The
number of strains of each species that were evaluated for
susceptibility to SbV and/or HePC, is summarized in Table 1.
Additionally, in order to characterize the profile of susceptibility to
SbV in an area of high transmission and long-term use of this
drug, we evaluated 170 clinical strains of L. V. panamensis isolated
from patients residing in transmission foci along the Rosario and
Mira rivers; 85 of the 170 strains were isolated between 1980 and
1989 following the initiation of the national leishmaniasis control
program, and 85 between 2000 and 2009; 13 of the latter strains
were included in the sample of L panamensis evaluated for
susceptibility to SbV and HePC from the Pacific Coast region.
Ethics statement
This study was approved and monitored by the Ethics
Committees of CIDEIM and CDFLLA for the use of Leishmania
strains and clinical information of the corresponding patients in
accordance with national and international guidelines for Good
Clinical Practice. Prior written informed consent for the use of
information from clinical histories had been obtained at the time
of diagnosis from patients included in this study.
Author Summary
Treatment of dermal leishmaniasis is unsuccessful in an
important proportion of cases and evidence of loss of
susceptibility to antimonial drugs and miltefosine has been
demonstrated in some cases of treatment failure with
these medications. Despite the variability in the clinical
outcome of treatment, little is known about the suscep-
tibility of the different species and diverse populations of
these species circulating in areas of high transmission.
Based on 402 strains isolated from patients, the suscep-
tibility of the Leishmania species most frequently causing
dermal leishmaniasis in Colombia was determined to first
and second line medications commonly used in Latin
America. The results showed that susceptibility to each
drug varied among the species and populations of each
species, geographically between regions east and west of
the Andes mountain range, during different time periods
over 30 years, and within different epidemiological
circumstances. The findings provide a comprehensive
picture of drug susceptibility of dermal leishmaniasis in
Colombia and baseline information for monitoring the
emergence of drug resistance.
Drug Susceptibility of L. Viannia in Colombia
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Resistant and sensitive lines of Leishmania
Internal standards consisting of the sensitive strain (MHOM/
COL/86/1166) and the experimentally derived SbV resistant line
(MHOM/COL/86/1166-1000.1) [23] and HePC resistant line
(MHOM/COL/86/1166-LUC056) [24] were included in each
experiment to confirm the discriminatory capacity of the assays.
The SbV and HePC resistant lines were propagated and
maintained in the presence of 1000 mmoles SbIII/L and 60 mmoles
HePC/L, respectively.
Drugs
Additive-free meglumine antimoniate (SbV; Walter Reed
214975AK; lot no. BLO918690-278-1A1W601; antimony analy-
sis, 25%–26.5% by weight) and 1-hexadecylphosphocholine
(HePC; miltefosine; Cayman Chemical Co., Ann Arbor, MI)
were utilized for in vitro susceptibility evaluation. Trivalent
antimony (SbIII) as potassium antimonyl tartrate thrihydrate was
obtained from Sigma–Aldrich Chemical Company, St. Louis,
MO.
In vitro assay for drug susceptibility using intracellular
amastigotes
Susceptibility was determined based on reduction of intracel-
lular parasite burden in U-937 macrophages (ATCC CRL-159.3)
as described by Ferna´ndez et al 2012 [24]. Briefly, 1.26105 U-937
cells were differentiated to macrophages by treatment with
phorbol 12-myristate 13-acetate (PMA; 100 ng/ml; Sigma), then
infected with promastigotes opsonized with 10% AB positive
human serum at a ratio of 5 parasites per macrophage. Infected
cells were incubated for 24 hours to allow differentiation of
intracellular parasites to amastigotes. Afterwards supernatants
were replaced with complete RPMI containing 16 mM HePC or
32 mg SbV/ml. In the case of SbV, medium containing 32 mg SbV/
ml was replenished 48 h later and incubation continued for an
additional 24 h. HePC exposure was conducted over 48 h without
replenishment [24].
Infection was assessed blindly by one of two experienced
microscopists who evaluated all slides for this study. Four
replicates of infected cells exposed to each drug and unexposed
infected control macrophages were evaluated. The number of
intracellular amastigotes per cell was determined for 100
macrophages per replica. Susceptibility was expressed as percent
reduction of infection, determined by comparing parasite burden
of infected cells exposed to the drug versus that of infected cells
without drug.
The cutoff defining sensitive and resistant strains for each drug
in vitro was based upon previously published analyses [24].
However, for the current study, an indeterminate range of
parasite reduction was defined based on the absence of data
within this range in the dataset used to derive the cutoff. Strains
presenting a reduction of parasite burden between 35% and 48%
for SbV and between 44% and 56% for HePC, were considered to
have indeterminate susceptibility, Supplemental Figure S1.
Therefore in vitro sensitivity or resistance was defined respectively
by reduction of parasite burden above or below the indeterminate
range for the corresponding drug.
Table 1. Species distribution of L. Viannia strains from regions of high prevalence evaluated in vitro for drug susceptibilitya.
Number of strains evaluated per species (%) Total Per Drug
L. V. panamensis L. V. braziliensis L. V. guyanensis
SbV 117 (57) 58 (28) 29 (15) 204
HePC 107 (52) 63 (31) 34 (17) 204
a163 strains were evaluated for both drugs, plus 41 for SbV only, and 41 for HePC only yielding a total of 204 strains for each drug and 245 for one or both drugs.
doi:10.1371/journal.pntd.0002871.t001
Figure 1. Susceptibility of L. Viannia species in Colombia to meglumine antimoniate and miltefosine. Reduction of parasite burden at the
discriminatory concentration of anti-leishmanial drugs for clinical strains of L. V. panamensis, L. V. braziliensis and L. V. guyanensis. The cutoff
thresholds (dotted horizontal line) of ,41% reduction of parasite burden by SbV (A) and ,50% reduction of parasite burden by HePC (B), and
indeterminate zones (gray region) were defined based on previously described ROC curves as reduction of parasite burden between 35% and 48% for
SbV and 44% and 56% for HePC (Fernandez O, et al 2012). a Strains presenting in vitro resistance. Kruskal-Wallis (K-W) for SbV: P = 0.0009 and K-W for
HePC: P,0.0001. * Dunn’s multiple comparison test P,0.05: Compared with L. V. braziliensis.
doi:10.1371/journal.pntd.0002871.g001
Drug Susceptibility of L. Viannia in Colombia
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Genotyping of strains by multilocus microsatellites
typing (MLMT)
In order to examine the relationship between genotypic
diversity and drug-susceptibility profiles, the relative genetic
diversity and proximity of L. V. panamensis strains pertaining to
zymodemes 2.2 (n = 10) and 2.3 (n = 10), plus 12 other strains of
this species without zymodeme classification from the Pacific coast
region, and L. V. guyanensis strains from the Amazon (n= 9) and
Andean region (n= 8) were analyzed by multilocus microsatellite
typing (MLMT). The geographic distribution of L. V. guyanensis
and its principal vector Lutzomyia umbratilis in Colombia, had
previously been limited to the Amazon River basin. Therefore, in
addition to drug susceptibility, the genetic diversity and relation-
ship of the L. V. guyanensis populations involved in the 2003–2005
epidemic of domestic transmission by Lutzomyia longiflucosa in
Chaparral, Tolima in the Andean foothills [25,26] and strains of L.
V. guyanensis from patients occupationally exposed to sylvatic
transmission in the Amazon region were also analyzed. DNA was
extracted from log-phase promastigotes using the Quigen Blood &
Tissue Kit (Qiagen, USA). Fourteen microsatellites distributed in
13 Leishmania chromosomes were amplified by PCR, as previously
described [27]. The size of the microsatellites was determined by
mobility of the PCR products in 4.5% agarose gels. Genetic
distances were estimated using MSA software and populations and
neighbor joining trees were constructed using MEGA 5.
Statistical methods
Strains of L. Viannia from each region were selected using a
simple random sampling technique. To explore differences in
susceptibility to SbV and HePC of Leishmania Viannia strains
according to species and geographic regions, Kruskal-Wallis (K-
W) tests and Dunn’s post-test for multiple comparisons were
performed. Differences in the susceptibility to SbV among L. V.
panamensis strains from two endemic foci during two 10-year time
periods, and between zymodeme 2.2 and 2.3 were analyzed using
the Mann-Whitney non-parametric test. Association between in
vitro susceptibility of L. V. panamensis to SbV and zymodeme, age or
occupation was examined using contingency tables (Chi square).
Comparison of proportions was calculated using the Z test.
Correlation of susceptibility to HePC and SbV was evaluated
based on the Spearman test. P values ,0.05 were considered
significant. Data were compiled in Microsoft Excel and analyzed
using Prism 5 (GraphPad, Inc).
Results
Drug susceptibility of Leishmania Viannia species
Susceptibility to SbV and HePC differed among strains of the
same species and between species of the (Viannia) subgenus
(Figure 1). Quantitative analysis showed that L. V. braziliensis
strains were significantly less susceptible to both drugs compared
with other (Viannia) species. Qualitative analysis with respect to the
cutoff thresholds and indeterminate zones of susceptibility in vitro
revealed that L. V. guyanensis presented the highest proportion of
sensitive strains for both drugs (82%, 28/34 for HePC and 86%,
25/29 for SbV) with only one strain being classified as resistant to
miltefosine and none for SbV, whereas L. V. braziliensis exhibited
the highest proportion of resistant strains (68% 43/63) for HePC
(P,0.05), yet a high proportion (69%, 40/58) were sensitive to
SbV. The in vitro susceptibility of a comparatively small proportion
overall of strains of these species of the Viannia subgenus fell within
the indeterminate range: 8% for SbV and 16% for HePC.
Analysis of the distribution of susceptibility of strains of each
species based on the median and inter-quartile range corroborated
the high susceptibility of L. V. panamensis and L. V. guyanensis strains
to SbV and HePC; over half of strains of these two species were
highly sensitive, with $79% and $70% reduction of infection
respectively, when exposed to 32 mg SbV/ml, and $66% and $
72% reduction respectively, when exposed to 16 mM HePC
(6.5 mg/mL). In contrast, 50% of L. V. braziliensis strains presented
in vitro resistance to the discriminatory concentration of HePC with
#32% reduction of parasite burden. However, the inter-quartile
distribution of the susceptibility of L. V. braziliensis strains to SbV
revealed that 50% of L. V. braziliensis strains were moderately
sensitive, with $58% reduction of parasite burden, and 25% were
highly sensitive with $76% reduction of infection.
Only 10% (16/163) of strains evaluated in vitro for both drugs
were resistant to both: 9% (7/80) L. V. panamensis and 17% (9/54)
L.V. braziliensis. While correlation analysis of all strains using the
Spearman test indicated a statistically significant relationship
between the susceptibility to each drug (P=0.0002), the attribut-
able effect was very low, r = 0.283.
Geographic variation in drug susceptibility
Exploratory analyses revealed geographic variation in drug
susceptibility of the L. Viannia species most prevalent in different
natural geographic regions. Strains from patients who acquired
infection in regions east of the Andes mountain ranges (Orinoquı´a
and Amazon regions) were significantly less susceptible to HePC
than strains from the Pacific Coast region on the western side of
the Andes, Figure 2. The lower susceptibility to HePC of strains
from Amazon was influenced principally by L. V. braziliensis (K-W:
P=0.0003, Dunn’s test: P,0.05). Strains originating from the
Orinoquı´a region presented the lowest susceptibility to both drugs.
Although most of the strains originating from this region were L. V.
braziliensis, L. V. panamensis strains from this region also contributed
to the lower susceptibility to HePC.
A significantly higher proportion of L. V. panamensis strains from
the Orinoquı´a and Amazon regions presented in vitro resistance to
HePC (46%, 11/24) compared with strains from Andean and
Pacific regions (14%, 5/35 and 10%, 5/48 respectively); however,
susceptibility of the same strains to SbV was similar across regions,
Figure 3A and B. Notably, strains presenting resistance to
miltefosine were isolated during and after 2005, and year of
isolation was inversely correlated with intracellular parasite
survival after exposure to 16 mM HePC (P=0.043, r =20.358)
Supplemental Figure S2. Though not statistically significant, L. V.
braziliensis strains from the Pacific region displayed greater
susceptibility to SbV compared with other regions, but were less
susceptible to HePC compared to strains of this species from other
regions, Figure 3 C and D.
Strains presenting resistance to both HePC and SbV originated
from the Andes, Orinoquia and Amazon regions. The frequency
distribution by species of these L. V. panamensis and L. V. braziliensis
strains displayed an inverse relationship from west to east of the
Andes, Supplemental Figure S3.
Susceptibility to antimony over time in Riverine foci of
Tumaco
Evaluation of the susceptibility to SbV among L. V. panamensis
strains (n = 170) from two endemic foci (Rosario and Mira Rivers)
in the municipality of Tumaco, during two 10 year periods over 3
decades, revealed that strains from patients from the Rosario River
focus presented a significantly lower median % reduction of
parasite burden (P,0.05) and higher frequency of in vitro resistance
to SbV during the decade 1980–89 (45%, 20/44) compared with
the decade from 2000–09 (25%, 6/24). In contrast, the median %
reduction of parasite burden was unchanged in the Mira River
Drug Susceptibility of L. Viannia in Colombia
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focus during the same periods but the frequency of resistance was
significantly higher (P,0.05) during the period 2000–09 (38%,
23/61) compared with the earlier period 1980–89 (17%, 7/41),
Figure 4A.
Surprisingly, discrete populations of L. V. panamensis were
discernible at the upper and lower limits of susceptibility in the
Rosario River focus during the period 1980–1989. Based on
the median and inter-quartile range, a high reduction of
parasite burden (.87%) was detected in 25% of strains and a
very low (,11%) reduction of parasite burden was evident in
25% of strains from the Rosario River focus during the
period 1980–1989. These populations continued to circulate
during 2000–2009 in both foci but in different proportions,
Figure 4A.
Epidemiologic analysis of susceptibility to antimonials
and isoenzyme polymorphism profile
Most L. V. panamensis strains isolated in the municipality of
Tumaco during the decade 1980–89 had been previously classified
by isoenzyme analysis as zymodeme 2.2 and 2.3, which
corresponded to the most common isoenzyme profiles of L. V.
panamensis in the southwestern region of Colombia [16]. Correla-
tion of zymodeme with susceptibility to SbV revealed a significant
association of the susceptibility phenotype with zymodeme (P,
0.05) among strains isolated during the period 1980-1989, when
zymodeme characterization was routine, Figure 4B and C. This
association was confirmed in 20 strains isolated during the decade
2000–2009 (data not shown). Most resistant strains from both
endemic foci pertained to zymodeme 2.3, whereas sensitive strains
Figure 2. Susceptibility of Leishmania Viannia species from major natural geographic regions to meglumine antimoniate and
miltefosine. Map of major natural geographic regions of Colombia (A). Susceptibility expressed as reduction of parasite burden at the discriminatory
concentration of SbV (B) and HePC (C) in clinical strains of L. V. panamensis, L. V. braziliensis and L. V. guyanensis. Distributions of % reduction of
parasite burden represent the median and the interquartile range. Qualitative classification of susceptibility is defined by the cutoff thresholds
(dotted horizontal line) and indeterminate ranges are illustrated by gray shading. K-W for SbV: P = 0.012 and K-W for HePC: P,0.0001. * Dunn’s
multiple comparison test P,0.05.
doi:10.1371/journal.pntd.0002871.g002
Drug Susceptibility of L. Viannia in Colombia
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pertained to zymodeme 2.2. Furthermore, strains of zymodeme
2.3 were significantly less susceptible to SbV than strains belonging
to zymodeme 2.2 (P,0.0001). Evaluation of these characteristics
in strains pertaining to zymodemes 2.2 and 2.3 from other
Departments within and outside of the Pacific coast region (n = 9),
corroborated the SbV sensitive and resistant phenotype of these
zymodemes that was observed in the Mira and Rosario River foci,
(Data not shown).
Multilocus microsatellite typing (MLMT) revealed genetic
diversity among the L. V. panamensis strains evaluated as well as
two independent clusters that coincided with zymodeme 2.2 and
zymodeme 2.3 and the susceptibility phenotype for antimonials,
Figure 5. L. V. guyanensis strains were also genetically diverse within
the two geographical regions represented; however, 6 of the 9
strains isolated in Chaparral, Tolima (Andean region) had
identical MLMT profiles, suggesting the predominance of a clonal
parasite population in this focus of transmission. No relationship
between MLMT genotype and susceptibility to SbV was evident
among the L. V. guyanensis strains, which displayed limited
variability in drug susceptibility.
Associations were also detected between zymodeme, patient age
and occupation. A significantly higher number of strains isolated
from children under seven years of age in the Municipality of
Tumaco pertained to zymodeme 2.3, Figure 6A. In contrast, a
significantly higher number of strains isolated from individuals
involved in agricultural activity pertained to zymodeme 2.2.
Frequency distributions of strains by zymodeme and according to
the age of the corresponding patient yielded epidemiologic profiles
characteristic of sylvatic transmission for zymodeme 2.2 and
domestic transmission for zymodeme 2.3, Figure 6B and 6C.
Discussion
This comprehensive evaluation of drug susceptibility of clinical
strains of Leishmania Viannia species is novel in several aspects: the
magnitude of the sample of clinical strains; the defined timeframes
and geographical distribution represented by the strains included;
the analyses of strains pertaining to three species of the Viannia
subgenus; and the correlation of susceptibility to SbV with
isoenzyme phenotype and demographic characteristics of the
corresponding patients. The results of this study provide a detailed
profile of susceptibility to meglumine antimoniate and miltefosine,
the first and second line drugs currently used to treat dermal
leishmaniasis in Colombia and most of Latin America, for the most
prevalent species in regions of high transmission in Colombia.
The clinical response to antimonial drugs and miltefosine in
different geographical contexts has long suggested differences in
drug efficacy for disease caused by different species. In this in vitro
analysis, strains of L. V. guyanensis, a species that has only recently
been encountered in the context of domestic transmission in
Colombia [25], were found to be consistently sensitive to both SbV
and HePC. In contrast, 20% of strains of L. V. panamensis, the most
Figure 3. Susceptibility of L. V. panamensis and L. V. braziliensis to meglumine antimoniate and miltefosine by geographic region.
Reduction of parasite burden at the discriminatory concentration of SbV (A and C) and HePC (B and D) for L. V. panamensis and L. V. braziliensis strains
from Pacific, Andean, Orinoquı´a and Amazon regions. Because of the lower frequency of L. V. panamensis in regions east of the Andes mountain
range, L. V. panamensis strains are combined for Orinoquı´a and Amazon regions. Qualitative classification of susceptibility is defined by the cutoff
thresholds (dotted horizontal line) and indeterminate ranges are illustrated by gray shading. K-W for L. V. panamensis and HePC, P = 0.0012 and Dunn
procedure, * P,0.05: Compared with Orinoquı´a and Amazon regions.
doi:10.1371/journal.pntd.0002871.g003
Drug Susceptibility of L. Viannia in Colombia
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prevalent species in Colombia [16,17,18] and frequently trans-
mitted in the domestic setting, were resistant to SbV or HePC in
vitro. Although a similar proportion of strains of L. V. braziliensis
were resistant to SbV, the reduction of parasite burden at the SbV
concentration approximating Cmax in plasma during treatment
was significantly lower for this species than for L. V. panamensis.
Furthermore, overall in vitro susceptibility of L. V. braziliensis strains
to miltefosine was remarkably low, with the majority (68%) being
resistant to 16 mM (6.5 mg/mL) miltefosine, a concentration that
distinguishes WT from experimentally selected lines [24]. This
finding concurs with the lower clinical response to HePC reported
in patients infected with L. V. braziliensis [4,20] in some
geographical areas [4] or occupational contexts [5].
In populations occupationally exposed to the sylvatic cycle of
transmission of L. V. braziliensis, such as military personnel, and in
regions where L. V. braziliensis is the predominant cause of dermal
leishmaniasis, the risk of poor therapeutic outcome with HePC
may be higher. Nevertheless, as for other antimicrobial agents, in
vitro susceptibility does not necessarily predict individual clinical
outcomes [28,29,30]. Rather, the risk or frequency of treatment
failure increases in relation with the minimum inhibitory drug
concentration (MIC) or IC50. However, clinical response, which is
multi-factorial, can be achieved despite in vitro resistance to a given
drug [31] as illustrated by the high proportion of dermal
leishmaniasis patients infected with L. V. braziliensis in Colombia,
Brazil and Bolivia that have responded to treatment with HePC
[5,7,8]. Nevertheless, the high frequency of in vitro resistance to
HePC among L. V. braziliensis strains circulating in Colombia
underscores the importance of systematic follow-up of treatment
and the rationale for combined therapies that could reduce the risk
of failure and selection of resistant populations.
Clinical response data and pharmacokinetic considerations of
drug exposure in designing and interpreting in vitro susceptibility
are sorely needed to reliably characterize the relationship between
clinical outcome and drug susceptibility. Recognizing that clinical
response and Leishmania species are not routinely determined
outside of clinical trials, this relationship would be most
informatively addressed within the scope of randomized, con-
trolled clinical trials in which many of the factors influencing
clinical response are controlled.
In vitro evaluation of anti-leishmanial drug susceptibility of
clinical strains relies on quantitative assessment of intracellular
survival of amastigotes following exposure of infected host cells to
the corresponding drugs [32,33]. The recent implementation of an
assay based on the burden of surviving intracellular parasites after
exposure to a single drug concentration that discriminates WT and
experimentally selected resistant populations [24] was critical to
the feasibility of this large scale study. The results substantiated a
Figure 4. Susceptibility of L. V. panamensis strains to meglumine antimoniate in endemic foci of Tumaco and association of drug
susceptibility with zymodeme. Distribution and median susceptibility of clinical strains from the Rosario River and Mira River foci during the
decades 1980–1989 and 2000–2009. K-W, P,0.0001 and Dunn procedure (A). Comparison of susceptibility of strains pertaining to zymodeme 2.3 and
zymodeme 2.2 isolated during 1980–1989 from the Rosario River and Mira River foci to SbV (B and C). Qualitative classification of susceptibility is
defined by the cutoff thresholds (dotted horizontal line) and indeterminate ranges are illustrated by gray shading. Mann-Whitney, P,0.0001.
doi:10.1371/journal.pntd.0002871.g004
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wide spectrum of susceptibility within each species, illustrating the
importance of evaluating a representative sample of strains that is
inclusive of the diversity of the species.
The analysis of clinical strains from different geographic regions
revealed lower susceptibility to both HePC and SbV among
populations of Leishmania originating east of the Andes mountain
range, an important natural geographic barrier. Although the
proportions of the three species from patients originating from the
eastern and western sides of the Andes differed, overall, Leishmania
strains from the Pacific and Andean regions were more sensitive to
both drugs than strains from Orinoquı´a and Amazon regions,
Figure 2. The finding that L. V. panamensis strains isolated from
patients originating in Orinoquı´a and the Amazon region were
significantly less susceptible to HePC than strains of this species
originating from the Andean and Pacific Coast regions, Figure 3,
raises the question of whether populations of this species acquired
by occupationally exposed individuals may have derived from a
cycle of transmission involving intrinsically less susceptible parasite
Figure 5. Analysis of genetic diversity of L. V. panamensis and L. V. guyanensis strains. The relationship between genetic diversity,
zymodeme, drug susceptibility and geographic distribution was examined based on an unrooted neighbor joining tree generated from the distances
calculated for microsatellite data. Strains included L. V. panamensis isolated from patients in the Municipality of Tumaco, Narin˜o pertaining to
zymodemes 2.3 (n = 10) and 2.2 (n = 10), L. V. panamensis strains from the Pacific coast region not typed by isoenzyme analysis, and L. V. guyanensis
strains isolated from patients from Andean (n = 9) and Amazon regions (n = 8). Range of susceptibility to antimony at 32 mg SbV/ml is shown for the
genetically discriminated groups of strains. ND* Zymodeme not determined.
doi:10.1371/journal.pntd.0002871.g005
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populations, or alternatively, might reflect exposure to HePC
treatment. Supporting the plausibility of drug pressure contribut-
ing to this pattern, the majority (79%) of L. V. panamensis strains
from Orinoquia and Amazonia derived from cases diagnosed after
2005, and HePC-resistant strains were isolated from 2005 onward
(Supplemental Figure S2), several from uniformed service person-
nel. However, multiple factors are likely to have contributed to the
relationship between year of isolation and resistance to HePC.
Zymodeme or microsatelite analyses of these strains may reveal
whether distinct populations of L. V. panamensis transmitted within
the ecological and epidemiological circumstances in these regions
contributed to the differences in susceptibility.
Examination of SbV susceptibility of L. V. panamensis strains
isolated during the decade 1980–1989 from patients of two
riverine foci in the municipality of Tumaco in relation with
zymodeme analysis [16], showed that resistant strains correspond-
ed with zymodeme 2.3 and susceptibilible to zymodeme 2.2. These
phenotypic differences were also discernible at the genetic level; L.
V. panamensis strains from both zymodemes independently
clustered in the display of MLMT analyses. This finding and the
confirmation of the susceptibility phenotypes of L. V. panamensis
strains of zymodeme 2.2 and 2.3 from other areas of transmission
within and outside of the Pacific coast region, provide compelling
evidence of intrinsic differences in susceptibility within this species.
Although unlikely to be directly involved in susceptibility to
antimonials, isoenzyme polymorphisms and/or microsatellites
associated with the susceptibility phenotype provide potentially
exploitable markers for epidemiological applications and clinical
decisions. These populations can also provide insight into the
mechanisms involved in their divergent susceptibilities to antimo-
ny that may be relevant and useful across species.
Low drug susceptibility may be an intrinsic and/or acquired
phenotype; a strain having low intrinsic susceptibility or tolerance
could become further unresponsive as evidenced by some strains
isolated pre-treatment with either SbV or HePC, and at treatment
failure [12,13]. Nevertheless, considering the long history of
monotherapeutic use of pentavalent antimonials in Colombia and
elsewhere in the region, evidence supporting the likelihood of
anthroponotic as well as zoonotic transmission, and the docu-
mentation of acquired resistance in prospectively isolated clinical
strains, the discrimination of intrinsic and/or acquired bases of
drug susceptibility phenotype remains challenging. Intrinsic
resistance to specific drugs resulting from absence of the
corresponding molecular target as seen in particular phylogenic
groups of bacteria has not been observed for any antileishmanial
drug. Monotherapy could amplify intrinsic resistance, as well as
promote acquired mechanisms. The biological cost or advantage
of loss of susceptibility and the role of anthroponotic transmission
Figure 6. Association of zymodeme, age and occupation in the Municipality of Tumaco. Children ,7 years of age were more frequently
infected with strains of L. V. panamensis pertaining to zymodeme 2.3, while farmers were more often infected by strains belonging to zymodeme 2.2.
n = 280 (A), Chi-square test, P,0.05. Distribution of L. V. panamensis strains belonging to zymodeme 2.2 (n = 181) and 2.3 (n = 149) by age of patients
with cutaneous leishmaniasis from the Municipality of Tumaco, 1980–1989 (B and C).
doi:10.1371/journal.pntd.0002871.g006
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will influence the impact of treatment policy and practice on the
drug susceptibility of prevalent Leishmania populations.
The observed association of Leishmania zymodeme with patient
occupation and age as well as parasite drug susceptibility in
endemic riverine foci of the municipality of Tumaco supports the
overlap of domestic and sylvatic transmission cycles among the
inhabitants of these communities. The SbV resistance phenotype
of zymodeme 2.3 and the association of this zymodeme with
children in the communities of Tumaco suggest that domestic
transmission may have been a factor in the emergence and
dissemination of the zymodeme 2.3 population of L. V. panamensis
in these foci during two decades spanning 30 years. The feasibility
of assessing drug susceptibility using a single drug concentration
and the precedent of being able to distinguish sensitive and
resistant strains based on an intrinsic biochemical profile such as
zymodeme provide opportunity to address this relationship.
Meanwhile, the spectrum of susceptibility and frequency of in vitro
resistance to first and second line treatments heighten the
importance of alternative and combination treatment strategies.
Supporting Information
Figure S1 Definition of discriminatory drug concentrations of
meglumine antimoniate and miltefosine for susceptibility determi-
nation in L. Viannia species. The cutoff thresholds (dotted vertical
line) of ,41% reduction of parasite burden by SbV (A) and ,50%
reduction of parasite burden by HePC (B), and indeterminate
zones (gray region) as reduction of parasite burden between 35%
and 48% for SbV and 44% and 56% for HePC were defined based
on previously described ROC curves (Fernandez O, et al 2012).
(TIF)
Figure S2 Correlation between year of isolation and miltefosine
susceptibility of L. V. panamensis strains from Amazon/Orinoquia
regions.
(TIF)
Figure S3 Geographic distribution by species, of strains
presenting in vitro resistance to both meglumine antimoniate and
miltefosine.
(TIF)
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